文献速递流行病学与生物统计临床试验与 GCP

新冠疫苗在免疫功能低下患者中的有效性:系统综述与Meta分析

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2022-03-02

该系统综述与Meta分析纳入82项前瞻性观察性研究,比较免疫功能低下与免疫功能正常人群接种新冠疫苗后的血清转化情况。结果显示,除HIV感染者外,免疫功能低下患者(尤其是器官移植受者)接种一剂或两剂后的血清转化率显著低于对照;第三剂mRNA疫苗与部分无应答者的血清转化相关。

要点

  • 器官移植受者接种一剂后血清转化风险比对照低约16倍(RR 0.06),第二剂后仅约三分之一发生血清转化。
  • 血液肿瘤、免疫介导炎症性疾病和实体癌患者接种一剂后血清转化率约为对照的一半,第二剂后明显改善。
  • HIV感染者接种后的血清转化率与免疫功能正常对照相似(RR 1.00)。

核心结论

  • 免疫功能低下患者接种新冠疫苗后的血清转化率显著低于免疫功能正常者,尤其是器官移植受者;第二剂可改善所有患者组的血清转化,但器官移植受者改善幅度较低;应针对免疫功能低下患者采取包括第三剂(加强针)在内的靶向干预。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Central Register of Controlled Trials、COVID-19 Open Research Dataset Challenge(CORD-19)及WHO covid-19数据库,纳入2020年12月1日至2021年11月5日发表的前瞻性观察性研究;另于2021年11月检索ClinicalTrials.gov和WHO国际临床试验注册平台以识别已注册但尚未发表或正在进行的研究。
  • Meta分析共纳入82项研究,其中77项(94%)使用mRNA疫苗,16项(20%)使用病毒载体疫苗,4项(5%)使用灭活全病毒疫苗;63项研究评估为低偏倚风险,19项为中等偏倚风险。
  • 采用频率学随机效应Meta分析分别合并第一剂和第二剂新冠疫苗后血清转化的相对风险和绝对风险;对第一、第二和第三剂后的SARS-CoV-2抗体滴度水平及第三剂后的血清转化率进行不合并效应的系统综述。

主要发现

  • 第一剂后,与免疫功能正常对照相比,血液肿瘤患者血清转化风险比(RR)为0.40(95%CI 0.32至0.50,I²=80%),绝对风险为0.29(95%CI 0.20至0.40,I²=89%);免疫介导炎症性疾病患者RR为0.53(95%CI 0.39至0.71,I²=89%),绝对风险为0.29(95%CI 0.11至0.58,I²=97%);实体癌患者RR为0.55(95%CI 0.46至0.65,I²=78%),绝对风险为0.44(95%CI 0.36至0.53,I²=84%);器官移植受者血清转化可能性比对照低16倍(RR 0.06,95%CI 0.04至0.09,I²=0%;绝对风险0.06,95%CI 0.04至0.08,I²=0%)。
  • 第二剂后,器官移植受者血清转化仍最低(RR 0.39,95%CI 0.32至0.46,I²=92%;绝对风险0.35,95%CI 0.26至0.46),仅约三分之一发生血清转化;血液肿瘤患者RR为0.63(95%CI 0.57至0.69,I²=88%),绝对风险0.62(95%CI 0.54至0.70,I²=90%);免疫介导炎症性疾病患者RR为0.75(95%CI 0.69至0.82,I²=92%),绝对风险0.77(95%CI 0.66至0.85,I²=93%);实体癌患者RR为0.90(95%CI 0.88至0.93,I²=51%),绝对风险0.89(95%CI 0.86至0.91,I²=49%)。
  • HIV感染者与免疫功能正常对照的血清转化率相似(RR 1.00,95%CI 0.98至1.01,I²=0%;绝对风险0.97,95%CI 0.83至1.00,I²=89%)。
  • 对11项研究的系统综述显示,第三剂新冠mRNA疫苗与实体癌、血液肿瘤和免疫介导炎症性疾病中疫苗无应答者的血清转化相关,但器官移植受者的应答可变,且在HIV感染者及接种非mRNA疫苗者中研究不足。

关键数值与推荐

  • 第一剂后血清转化相对风险:血液肿瘤RR 0.40(95%CI 0.32至0.50),免疫介导炎症性疾病RR 0.53(95%CI 0.39至0.71),实体癌RR 0.55(95%CI 0.46至0.65),器官移植受者RR 0.06(95%CI 0.04至0.09),HIV感染者RR 1.00(95%CI 0.98至1.01)。
  • 第二剂后血清转化相对风险:器官移植受者RR 0.39(95%CI 0.32至0.46),血液肿瘤RR 0.63(95%CI 0.57至0.69),免疫介导炎症性疾病RR 0.75(95%CI 0.69至0.82),实体癌RR 0.90(95%CI 0.88至0.93)。
  • 第三剂mRNA疫苗与实体癌、血液肿瘤和免疫介导炎症性疾病中疫苗无应答者的血清转化相关,但器官移植受者应答可变,HIV感染者及接种非mRNA疫苗者研究不足。

临床怎么用

  • 作者认为,应针对免疫功能低下患者采取靶向干预,包括第三剂(加强针)接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of covid-19 vaccines between immunocompromised and immunocompetent people. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, Central Register of Controlled Trials, COVID-19 Open Research Dataset Challenge (CORD-19), and WHO covid-19 databases for studies published between 1 December 2020 and 5 November 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in November 2021 to identify registered but as yet unpublished or ongoing studies. STUDY SELECTION: Prospective observational studies comparing the efficacy of covid-19 vaccination in immunocompromised and immunocompetent participants. METHODS: A frequentist random effects meta-analysis was used to separately pool relative and absolute risks of seroconversion after the first and second doses of a covid-19 vaccine. Systematic review without meta-analysis of SARS-CoV-2 antibody titre levels was performed after first, second, and third vaccine doses and the seroconversion rate after a third dose. Risk of bias and certainty of evidence were assessed. RESULTS: 82 studies were included in the meta-analysis. Of these studies, 77 (94%) used mRNA vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole virus vaccines. 63 studies were assessed to be at low risk of bias and 19 at moderate risk of bias. After one vaccine dose, seroconversion was about half as likely in patients with haematological cancers (risk ratio 0.40, 95% confidence interval 0.32 to 0.50, I2=80%; absolute risk 0.29, 95% confidence interval 0.20 to 0.40, I2=89%), immune mediated inflammatory disorders (0.53, 0.39 to 0.71, I2=89%; 0.29, 0.11 to 0.58, I2=97%), and solid cancers (0.55, 0.46 to 0.65, I2=78%; 0.44, 0.36 to 0.53, I2=84%) compared with immunocompetent controls, whereas organ transplant recipients were 16 times less likely to seroconvert (0.06, 0.04 to 0.09, I2=0%; 0.06, 0.04 to 0.08, I2=0%). After a second dose, seroconversion remained least likely in transplant recipients (0.39, 0.32 to 0.46, I2=92%; 0.35, 0.26 to 0.46), with only a third achieving seroconversion. Seroconversion was increasingly likely in patients with haematological cancers (0.63, 0.57 to 0.69, I2=88%; 0.62, 0.54 to 0.70, I2=90%), immune mediated inflammatory disorders (0.75, 0.69 to 0.82, I2=92%; 0.77, 0.66 to 0.85, I2=93%), and solid cancers (0.90, 0.88 to 0.93, I2=51%; 0.89, 0.86 to 0.91, I2=49%). Seroconversion was similar between people with HIV and immunocompetent controls (1.00, 0.98 to 1.01, I2=0%; 0.97, 0.83 to 1.00, I2=89%). Systematic review of 11 studies showed that a third dose of a covid-19 mRNA vaccine was associated with seroconversion among vaccine non-responders with solid cancers, haematological cancers, and immune mediated inflammatory disorders, although response was variable in transplant recipients and inadequately studied in people with HIV and those receiving non-mRNA vaccines. CONCLUSION: Seroconversion rates after covid-19 vaccination were significantly lower in immunocompromised patients, especially organ transplant recipients. A second dose was associated with consistently improved seroconversion across all patient groups, albeit at a lower magnitude for organ transplant recipients. Targeted interventions for immunocompromised patients, including a third (booster) dose, should be performed. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021272088.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022. PMID: 35236664. doi:10.1136/bmj-2021-068632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。